According to the latest market research study released by Technavio, the global cystic fibrosis therapeutics market is expected to grow at a CAGR of close to 32% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global cystic fibrosis therapeutics market based on drug type:
Global cystic fibrosis therapeutics market share by drug type 2015
|
CFTR |
27.29% |
|
Mucolytics |
22.00% |
|
PERT |
21.00% |
|
Anti-infectives |
19.00% |
|
Bronchodilators |
10.71% |
Source: Technavio
The top four revenue contributing drug segments are discussed below:
CFTR modulators
In 2015, CFTR modulators accounted for around 27% of the global cystic fibrosis therapeutics market. They are physically small molecules that target defects specifically caused by CFTR gene mutations. CFTR modulators can be classified in three categories such as potentiators, correctors, and read through agents or production correctors. Each subclass drugs have a specific mechanism of action which is described by their nomenclature. These drugs target different mutations and act accordingly. In this sub class drugs, the CFTR potentiators are used to increase the functions of CFTR channels that are present on the surface of the cell. The correctors are used to expand the processing and delivery of a functional CFTR protein to the surface of the cell, resulting in facilitation of ion transportation by increasing the amount of CFTR protein on the surface of the cell. The production correctors that helps in the promotion of the read-through of premature termination codons, is also known as read-through agents. CFTR potentiators act on the basis of two factors that include gating defects or conduction defects. Kalydeco (ivacaftor) is the only CFTR potentiator available in the market for the treatment of cystic fibrosis.
“It has been observed that there is an increased uptake of CFTR modulators. One of the strong properties of CFTR modulator drugs which make them preferable is that they target the molecular cause of cystic fibrosis and help in effective treatment rather than just providing the temporary relief. Kalydeco and Orkambi are the CFTR modulators that have been approved and marketed for the treatment of cystic fibrosis,” says Sapna Jha, a senior analyst at Technavio for research on cardiovascular and metabolic disorders.
Mucolytics
In 2015, mucolyctics accounted for around 22% of the global cystic fibrosis therapeutics market. Mucolytics are popular as the mucus thinning agents help in easy ejection of mucus from lungs. Mucolytics effectively reduces the thickness and elasticity of mucus, resulting in easy ejection. The mucus thinners used in the treatment of cystic fibrosis are pulmozyme and hypertonic saline.
PERT
PERT accounted for around 21% of the global cystic fibrosis therapeutics market in 2015. Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes. These effective therapeutics help the body in absorbing nutrients from the food and facilitates digestion process. Around 70%-85% of the cystic fibrosis patients are estimated to consume PERT, few PERTs available in the market are Zenpep, Viokase, Ultresa, Pancreaze, and Creon.
Anti-infectives
In 2015, Anti-infectives accounted for around 19% of the global cystic fibrosis therapeutics market. Anti-infectives or antibiotics are small molecules that kill or inhibit the growth of microorganisms. There are two ways of its production that include derived from natural compounds and synthesized under laboratory conditions. At present, drug makers are synthetically manufacturing most of the modern drugs on a large scale. For the treatment of cystic fibrosis, the antibiotics that are available in the market are TOBI and TOBI Podhaler (tobramycin) by Novartis and Cayston (aztreonam) by Gilead Sciences.
The top leading vendors operating in the global cystic fibrosis therapeutics market are:
- Vertex Pharmaceuticals
- F. Hoffmann-La Roche
- AbbVie
- Gilead Sciences
- Novartis
Other prominent vendors in the market include Advanced Inhalation Therapies, Alaxia SAS, Alcresta Therapeutics, AlgiPharma, Allergan, Anthera, AstraZeneca, Bayer, Celtaxsys, Chiesi Farmaceutici, Corbus Pharmaceuticals, Cyclacel Pharmaceuticals, Digestive Care, Galapagos, Grifols, Insmed Incorporated, Kamada, Nivalis Therapeutics, Novoteris, Parion Sciences, Pharmaxis, ProQR Therapeutics, Protalix Biotherapeutics, Proteostasis Therapeutics, PTC Therapeutics, Pulmatrix, Savara, SolAeroMed, and Vectura.
A more detailed analysis is available in the Technavio report titled, ‘Global Cystic Fibrosis Therapeutics Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Cystic Fibrosis Market in Europe 2015-2019
- Global Idiopathic Pulmonary Fibrosis Market 2016-2020
- Global Genetic Testing Market 2015-2019
- Global Molecular Diagnostics Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
